UNITED STATES PATENT AND TRADEMARK OFFICE

_____

BEFORE THE PATENT TRIAL AND APPEAL BOARD

_____

Celltrion, Inc.

Petitioner,

v.

Genentech, Inc.

Patent Owner

Patent No. 6,407,213

_____

Inter Partes Review No. IPR2017-01374

_____

**EXPERT DECLARATION OF LUTZ RIECHMANN, PH.D.
IN SUPPORT OF PETITIONER'S REPLY TO PATENT OWNER'S
RESPONSE**

I, Lutz Riechmann, Ph.D. declare as follows:

I. Introduction

1. I am the same Lutz Riechmann who submitted a declaration in support of Celltrion's Petition for Inter Partes Review of U.S. Patent 6,407,213 (the '213 patent) in May 2017. A detailed description of my background and qualifications may be found in that declaration, which I refer to as my "first declaration." In addition to the materials listed in Exhibit 1003B to my first declaration, I have also considered the materials set forth in the Addendum to this declaration.

2. I am being compensated at my standard rate for my time spent preparing this declaration, and my compensation is not contingent on the outcome of any matter or on any of the opinions provided below. I have no financial interest in the outcome of this proceeding.

3. I provided my understanding of legal concepts as they relate to this proceeding in my first declaration. My understanding of those concepts has not changed since I submitted my first declaration.

II. Opinions

A. <u>A Person of Ordinary Skill In the Art Would Understand that The Disclosure of the Patent Is Limited</u>

4. A person of ordinary skill would understand that the patent does not teach that all of the claimed back mutations and possible combinations of back

mutations will improve the binding of all antibodies that could be covered by the claims, or that any specific back mutation will work for a specific antibody other than those in the examples that were tested for binding. A person of ordinary skill would have understood from the prior art disclosing the specific structures of humanized antibodies, as well as the examples in the patent, that the back mutations that will increase binding will vary from antibody to antibody. The patent requires a person of ordinary skill to construct models to determine which of the described back mutations might possibly improve binding in a given project, and then use mutagenesis, which is the making of antibodies with different back mutations and then testing them, to confirm which precise combination of mutations works best to increase binding. A person of ordinary skill would have understood that there is no significant difference between this method and the methods in Queen 1989 and 1990 and the other prior art I have cited.

      B.   <u>A Person of Ordinary Skill in the Art Would Have Been Motivated to Combine Queen 1989 and/or Queen 1990 with the PDB</u>

      5.   Dr. Wilson argues that a person of ordinary skill in the art would not have combined the PDB with either of Queen 1989 or Queen 1990 in the manner I described in my first declaration. (Ex. 2041 (Wilson Decl. for IPR2017-01373) at ¶¶ 177-84.) I do not agree with Dr. Wilson's criticisms. As I explained in my first declaration, a person of ordinary skill would have used the publically available x-ray crystallographic studies of antibodies in the PDB during the humanization

2

process, because the PDB database provided a collection of the available antibody structures at that time. In fact, a person of ordinary skill in the art would have known it would not have been possible to create an accurate molecular model without using the information put forth in the PDB (or similar database). As I discussed, a person of ordinary skill could have processed the information either using one of a number of commercially available software packages such as CONTAX, PAIRS, or MIDAS, or could have done the calculations using a spreadsheet program such as Microsoft Excel. Regardless of the mechanism used to do these calculations, the results would have been the same.

6.   Further, Dr. Wilson's assertion that Queen 1989 and Queen 1990 would have taught a POSA to model structure of the parent murine antibody and not the human framework is immaterial to my analysis. Regardless of whether the starting point was the murine structure or a humanized structure, a person of ordinary skill in the art would have used the data from the three-dimensional model to locate the framework residues that could, because of their positions within the heavy and light chains of the variable domain, either alter the structure of the CDRs or interact directly with the antigen during binding. A person of ordinary skill also would have regarded the Queen methodology as a reliable means of identifying framework substitutions that could be used to improve binding affinity. Dr. Wilson has not explained any reason why the outcome of the identification of

3

possible framework residues for substitution would be different if the person of ordinary skill modeled the human framework with the murine CDRs inserted within it, and I am not aware of any reason.

7.   Also, Queen 1989 considered "other antibody V domains with known crystal structure" when constructing the antibody models used in Queen's method, (Ex. 1034 (Queen 1989) at 3), and Queen 1990 disclosed using "known structures" of the mAbs in the PDB as rough models that could be used to help construct the antibody models used in Queen's method. (Ex. 1050 (Queen 1990) at 16, 14:32-36.)

C.   Dr. Wilson Ignores the Impact of Interspecies Homology

8.   Dr. Wilson suggests that my analysis is flawed because the references on which I rely disclose additional potential residue back mutations that I did not specifically address and asserts that a person of ordinary skill in the art would not have been able to select the relevant back-mutations for a given humanized antibody from this larger group. (Ex. 2041 (Wilson Decl.) at ¶¶ 227-34.) I disagree.

9.   As the '213 patent acknowledges, while the number of potential back mutations in any humanization project can be relatively large, the process of identifying which residues from this set of potential back mutations are more likely than others to improve the binding of a given humanized antibody would have

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.

WHAT WILL YOU BUILD? | sales@docketalarm.com | 1-866-77-FASTCASE

fastcase®
Smarter legal research.